Aldeyra The (ALDX NASDAQ) stock market data APIs
$0.9396
0.02(2.1%)
as of October 8, 2026
Try our APIs with
free plan!
Aldeyra The Financial Data Overview
Price chart is built with
Anychart
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Prev. Close
0.9396
Open
0.9547
High
0.9647
Low
0.9042
52 wk Range
0.8619-5.93
Market Cap
57 829 K
Shares Outstanding
60 326 K
EPS
-0.16
Beta
1.2
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aldeyra The (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aldeyra The data using free add-ons & libraries
Get Aldeyra The Fundamental Data
Aldeyra The Fundamental data includes:
- Net Revenue:
- EBITDA: -23 800 336
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aldeyra The News
New
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine LPCN is an emerging specialty pharmaceutical company focused on developing oral therapies for diseases with significant unmet medical needs. The company offers a mix of an approved commercial...
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Ultragenyx Pharmaceutical RARE has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The transaction is expected to provide the rare-...
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Shares of Eton Pharmaceuticals ETON have gained about 108% over the past six months compared with the industry's 0.7% growth, fueled by growing investor confidence in the company's strong commercial e...
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Shares of Agios Pharmaceuticals AGIO have declined 29% over the past three months despite strong growth in mitapivat sales in the second quarter of 2026. The decline largely reflects setbacks to tebap...
Get Aldeyra The fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.